Answers are grounded in this paper and cite their sources.
Multidrug resistance (MDR) is frequent in non-small cell lung cancer (NSCLC) patients, which can be due to its fibrotic stroma. This work explores the combination of pentoxifylline, an anti-fibrotic and chitinase 3-like-1 (CHI3L1) inhibitor drug, with conventional chemotherapy to improve NSCLC treatment.
No takes yet. Share an insight, caveat, or question.
Matos et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: